Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

about

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

Item

http://www.wikidata.org/entity/Q47198620

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

@en

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

@nl

type

Item

label

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

@en

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

@nl

prefLabel

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

@en

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

@nl

P1476

Cost Effectiveness of Gene Expression Profile Testing in Community Practice

@en

P2093

Aimee Near

http://www.w3.org/2001/XMLSchema#string

Charles E Phelps

http://www.w3.org/2001/XMLSchema#string

Clyde B Schechter

http://www.w3.org/2001/XMLSchema#string

G Thomas Ray

http://www.w3.org/2001/XMLSchema#string

Jeanne S Mandelblatt

http://www.w3.org/2001/XMLSchema#string

Scott Ramsey

http://www.w3.org/2001/XMLSchema#string

Suzanne C O'Neill

http://www.w3.org/2001/XMLSchema#string

Tracy A Lieu

http://www.w3.org/2001/XMLSchema#string

Young Chandler

http://www.w3.org/2001/XMLSchema#string

P2860

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.

Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.

Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.

Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.

Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.

P304

554-562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2017.74.5034

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jinani Jayasekera

Claudine Isaacs

P577

2018-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29309250

http://www.w3.org/2001/XMLSchema#string

P932

5815401

http://www.w3.org/2001/XMLSchema#string